Becton, Dickinson and Company (BDX) Receives $199.54 Consensus PT from Analysts

Shares of Becton, Dickinson and Company (NYSE:BDX) have received an average rating of “Buy” from the seventeen ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $199.54.

A number of analysts have weighed in on the company. Barclays PLC restated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Receives $199.54 Consensus PT from Analysts” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/10/10/becton-dickinson-and-company-bdx-receives-199-54-consensus-pt-from-analysts.html.

Shares of Becton, Dickinson and (NYSE:BDX) traded down 0.43% on Friday, reaching $196.29. The company had a trading volume of 1,061,161 shares. The company has a 50 day moving average of $197.20 and a 200-day moving average of $192.71. The company has a market capitalization of $44.67 billion, a P/E ratio of 56.85 and a beta of 1.05. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the firm earned $2.35 earnings per share. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. Analysts predict that Becton, Dickinson and will post $9.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.49%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last 90 days. 1.40% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of BDX. BlackRock Inc. increased its position in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares during the period. Koch Industries Inc. increased its position in Becton, Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after acquiring an additional 1,395,182 shares during the period. Vanguard Group Inc. increased its position in Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares during the period. Winslow Capital Management LLC acquired a new position in Becton, Dickinson and in the 2nd quarter valued at about $225,164,000. Finally, Janus Henderson Group PLC increased its position in Becton, Dickinson and by 1,265.9% in the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after acquiring an additional 1,122,191 shares during the period. Hedge funds and other institutional investors own 87.12% of the company’s stock.

A number of analysts have weighed in on the company. Barclays PLC restated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Receives $199.54 Consensus PT from Analysts” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/10/10/becton-dickinson-and-company-bdx-receives-199-54-consensus-pt-from-analysts.html.

Shares of Becton, Dickinson and (NYSE:BDX) traded down 0.43% on Friday, reaching $196.29. The company had a trading volume of 1,061,161 shares. The company has a 50 day moving average of $197.20 and a 200-day moving average of $192.71. The company has a market capitalization of $44.67 billion, a P/E ratio of 56.85 and a beta of 1.05. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the firm earned $2.35 earnings per share. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. Analysts predict that Becton, Dickinson and will post $9.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.49%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last 90 days. 1.40% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of BDX. BlackRock Inc. increased its position in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares during the period. Koch Industries Inc. increased its position in Becton, Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after acquiring an additional 1,395,182 shares during the period. Vanguard Group Inc. increased its position in Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares during the period. Winslow Capital Management LLC acquired a new position in Becton, Dickinson and in the 2nd quarter valued at about $225,164,000. Finally, Janus Henderson Group PLC increased its position in Becton, Dickinson and by 1,265.9% in the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after acquiring an additional 1,122,191 shares during the period. Hedge funds and other institutional investors own 87.12% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply